We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+30.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$318M
AUM Growth
+$98.7M
Cap. Flow
+$13.5M
Cap. Flow %
4.23%
Top 10 Hldgs %
67.71%
Holding
36
New
11
Increased
7
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$19.3M
2
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.1M
3
CYTK icon
Cytokinetics
CYTK
+$13.9M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$9.48M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.55M

Top Sells

Rank Stock Value
1
ATRA icon
Atara Biotherapeutics
ATRA
+$25.3M
2
EPZM
Epizyme, Inc
EPZM
+$11.8M
3
KITE
Kite Pharma, Inc.
KITE
+$8.12M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$2.58M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$1.98M

Sector Composition

Rank Sector Weight
1 Healthcare 77.71%
2 Miscellaneous 22.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
1
Kyntra Bio
KYNB
$32.5M
$37.1M 11.64%
48,659
-557
-1% -$370K
FPRX
2
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$29.8M 9.37%
719,000
+570,000
+383% +$19.1M
JAZZ icon
3
CALL
Jazz Pharmaceuticals
JAZZ
$15.9B
$26.6M 8.35%
+189,200
New +$26.2M
TVTX icon
4
Travere Therapeutics
TVTX
$6.19B
$23.6M 7.42%
1,224,384
+216,724
+22% +$4.33M
KURA icon
5
Kura Oncology
KURA
$1.13B
$20.6M 6.46%
+2,450,000
New +$19.3M
ASMB icon
6
Assembly Biosciences
ASMB
$694M
$15.8M 4.95%
174,859
+17,603
+11% +$1.92M
CYTK icon
7
Cytokinetics
CYTK
$10B
$14.8M 4.66%
+1,418,700
New +$13.9M
BHC icon
8
CALL
Bausch Health
BHC
$2.36B
$12.9M 4.04%
126,500
+125,235
+9,900% +$14.1M
COLL icon
9
Collegium Pharmaceutical
COLL
$786M
$12.8M 4.02%
465,118
– –
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$11.2M 3.52%
698,900
-793,800
-53% -$11.8M
LKFT
11
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$10.5M 3.31%
+167,361
New +$8.55M
KITE
12
DELISTED
Kite Pharma, Inc.
KITE
$10.2M 3.21%
166,000
-115,400
-41% -$8.12M
DCOY
13
Decoy Therapeutics
DCOY
$1.9M
$9.9M 3.11%
1
– –
IRWD icon
14
Ironwood Pharmaceuticals
IRWD
$682M
$9.52M 2.99%
+980,908
New +$9.48M
NBRV
15
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.93M 2.49%
3,355
+13
+0.4% +$31.7K
ATYR
16
aTyr Pharma
ATYR
$53M
$7.77M 2.44%
56,462
-3,571
-6% -$508K
KIN
17
DELISTED
Kindred Biosciences, Inc.
KIN
$4.87M 1.53%
1,432,765
+109,334
+8% +$507K
TVTX icon
18
CALL
Travere Therapeutics
TVTX
$6.19B
$4.71M 1.48%
+244,100
New +$4.88M
EIGR
19
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$4.18M 1.31%
6,318
– –
TPST icon
20
Tempest Therapeutics
TPST
$17.5M
$4.15M 1.3%
+145
New +$4.78M
GNVC
21
DELISTED
GenVec, Inc.
GNVC
$3.53M 1.11%
192,091
-6,550
-3% -$125K
CALA
22
DELISTED
Calithera Biosciences, Inc
CALA
$3.18M 1%
20,774
– –
CYTK icon
23
CALL
Cytokinetics
CYTK
$10B
$2.98M 0.94%
+284,600
New +$2.79M
LRMR icon
24
Larimar Therapeutics
LRMR
$417M
$2.32M 0.73%
+30,750
New +$4.94M
FWP
25
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.9M 0.6%
14,288
-283
-2% -$45.4K
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2015 Portfolio in Review

As of Q4 2015, EcoR1 Capital held 36 positions worth $318M, up 45% from $220M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital deployed $13.5M of net new capital in Q4 2015, opening 11 new positions and adding to 7 existing holdings. Its largest new stake was Kura Oncology: 2,450,000 shares worth $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 88% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Epizyme, Inc, an estimated $11.8M trimmed.

  • EcoR1 Capital's largest Q4 2015 buy was Kura Oncology: 2,450,000 shares worth $20.6M.
  • EcoR1 Capital added most to Five Prime Therapeutics, Inc. in Q4 2015, an estimated $19.1M increase.
  • EcoR1 Capital's biggest Q4 2015 reduction was Epizyme, Inc, cutting an estimated $11.8M.
  • EcoR1 Capital fully exited Atara Biotherapeutics in Q4 2015, selling an estimated $25.3M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $318M portfolio in Q4 2015.
  • EcoR1 Capital opened 11 new positions and closed 5 in Q4 2015.
  • EcoR1 Capital's portfolio value rose 45% quarter-over-quarter to $318M.

Based on EcoR1 Capital's 13F filing for Q4 2015, filed 16 Feb 2016.